The non-profit Global Drug Facility (GDF), a division of the Stop TB Partnership, has announced a price reduction for the life-saving drug used to treat drug-resistant tuberculosis (DR-TB) — bedaquiline. A full treatment course produced by Lupin will now be available at USD 63, representing a 30% decrease, while the cost of the full BPaL(M) regimen will fall below USD
As part of its annual activities, the Eurasian Community for Access to Treatment (ECAT) will organize several online meetings with pharmaceutical companies to discuss issues related to the registration, pricing, and availability of essential medicines in Eastern Europe and Central Asia (EECA).
TB Europe Coalition invites everyone to join the educational webinar “Strengthening Community Knowledge and Engagement in the Development of National Strategic Plans (NSPs)”, which will take place on 17 September 2025, from 11:00 to 12:30 CET. You can register via this link.
The U.S. Department of State, Gilead Sciences, and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the launch of a large-scale initiative to expand access to lenacapavir — the first injectable HIV prevention medication administered just twice a year.
The Civil Society Engagement Mechanism for UHC2030 (CSEM) is now accepting nominations for nine open positions on its Advisory Group.
In 2023–2024, our partners in Kyrgyzstan and Belarus conducted an assessment of access to viral load and drug resistance testing. Our team has prepared a summary report based on data collected over the past year, providing an analysis of the current situation in both countries.
Three representatives from the EECA region were elected to the Community Delegation of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria: Denis Godlevskiy, Regional Coordinator of ITPC EECA, Valeriia Rachynska, Director of the Communities Development Department of theCharitable Organization “100%LIFE” and Lyubov Vorontsova, representative of the Eurasian Women’s Network on AIDS and member of the Steering
September 3, twenty-five patient organizations working in the field of HIV response in Russia published an open letter to Gilead Sciences, asking the pharmaceutical company to disclaim patent rights for the combination of tenofovir and emtricitabine, marketed under the tradename Truvada.
ITPCru team is glad to present their report on ARVs procurement monitoring in Russia in 2018.
ITPCru is proud to present its first regional report on procurement and provision of antiretroviral drugs in 7 countries of Eastern Europe and Central Asia in 2017. The report is based on a series of national reports implemented by patient organizations in the respective countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Ukraine).
